Ignite Creation Date:
2025-12-25 @ 4:07 AM
Ignite Modification Date:
2026-01-28 @ 9:46 PM
Study NCT ID:
NCT01656720
Status:
COMPLETED
Last Update Posted:
2015-06-09
First Post:
2012-08-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D004688', 'term': 'Encopresis'}], 'ancestors': [{'id': 'D012817', 'term': 'Signs and Symptoms, Digestive'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D001526', 'term': 'Behavioral Symptoms'}, {'id': 'D001519', 'term': 'Behavior'}, {'id': 'D019960', 'term': 'Elimination Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 417}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2015-06', 'completionDateStruct': {'date': '2014-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2015-06-08', 'studyFirstSubmitDate': '2012-08-01', 'studyFirstSubmitQcDate': '2012-08-01', 'lastUpdatePostDateStruct': {'date': '2015-06-09', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2012-08-03', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Evaluate the efficacy of NRL001 in faecal incontinence by assessing the improvement of the incontinence status after 4 weeks of treatment compared to baseline by means of the Wexner score', 'timeFrame': 'Up to 8 weeks'}], 'secondaryOutcomes': [{'measure': 'To provide data on the efficacy of NRL001 in patients with faecal incontinence over an 8 week treatment period', 'timeFrame': '8 weeks'}, {'measure': 'To provide preliminary data on the safety and tolerability of NRL001 (5mg, 7.5mg and 10mg) over an 8 week treatment period compared to placebo', 'timeFrame': '8 weeks'}, {'measure': 'To evaluate the population pharmacokinetics and to establish any pharmacokinetic/pharmacodynamic relationship with adverse events', 'timeFrame': '8 weeks'}, {'measure': 'To evaluate the dose-response relationship in order to identify the appropriate dose(s) of NRL001 for future studies', 'timeFrame': '8 weeks'}, {'measure': "To evaluate the effect of treatment according to the patient's Faecal Incontinence Quality of Life questionnaire at 4 and 8 weeks", 'timeFrame': '8 weeks'}, {'measure': 'To evaluate the effect of treatment according to the Vaizey score at 4 and 8 weeks', 'timeFrame': '8 weeks'}]}, 'conditionsModule': {'keywords': ['Faecal Incontinence', 'Suppository', 'Wexner score'], 'conditions': ['Faecal Incontinence']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the safety, tolerability and efficacy of NRL001 in the treatment of faecal incontinence, compared against placebo'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* An ultrasound assessment of the internal anal sphincter within the previous 12 months confirming an intact circular internal sphincter with minimal scars (maximum 60 degrees scarring circumferentially).\n* Diagnosis of faecal incontinence with a Wexner score of 8 - 20 inclusive at Visit 1 - Screening Visit.\n* Historical clinical evidence (past 6 months prior to Visit 1 - Screening Visit) of faecal incontinence episodes (solids, liquid, gas or mucus).\n* Greater than or equal to two faecal incontinence episodes (solids, liquid, gas or mucus) per week during the 4 week historical period prior to Visit 1 - Screening Visit.\n* Able and willing to receive rectal examinations and treatments.\n* Patients must be aged \\>18 without significant acute or uncontrolled chronic disease.\n* Patients must understand the purpose and risks of the study and be able to provide written informed consent and willing, able and competent to complete the entire study and comply with study instructions as defined in the protocol.\n* Female patients must be postmenopausal (for at least one year and confirmed by serum FSH at screening), or surgically sterile, practicing true sexual abstinence, or using Investigator-approved methods of contraception throughout the study until after the post study physical examination and have a negative pregnancy test at screening.\n* Sexually active male patients must use condoms with their partners throughout the study and for 90 days after completion of the study in addition to their partner's normal mode of contraception.\n* Male patients must not donate sperm during the study and for 90 days after the completion of the study.\n* Patients taking any continuous medication need to have been on a stable regimen for at least 1 month prior to Visit 1 - Screening Visit.\n\nExclusion Criteria:\n\n* External anal sphincter disruption related to faecal incontinence caused by trauma.\n* Patients with complicating gastrointestinal (GI) disease including those with inflammatory bowel diseases, patients that have received radiotherapy or surgery for anal cancer, patients with rectal prolapse, transanal surgery.\n* Relevant history of or presence of any significant or uncontrolled cardiovascular risk including:\n\n 1. Systolic \\> 160mmHg or Diastolic \\> 100mmHg. Patients on a stable regimen for \\> 3 months with controlled hypertension prior to Visit 1 - Screening Visit (Systolic \\< 140mmHg or Diastolic \\< 90mmHg) can be included.\n 2. Abnormal 24 hour Screening Holter: corrected QT interval (QTcf) prolongation with cut-off values of \\>460 ms for females and \\>430 ms for males, acute arrhythmia, nocturnal bradycardia with heart rate (HR) \\< 40bpm, atrial fibrillation, AV block Type II and III, Sick Sinus Syndrome, vasovagal syncope.\n 3. Fixed cardiac output states (severe aortic stenosis (AS), hypertrophic obstructive cardiomyopathy (HOCM).\n 4. Significant mitral regurgitation (MR).\n 5. Cardiac failure (New York Heart Association (NYHA) stage II-IV).\n* Severe or uncontrolled asthma or chronic obstructive pulmonary disease determined by clinical history, physical examination, lung function tests or exercise tolerance\n* Chronic liver disease (e.g. liver cirrhosis, chronic hepatitis, severe hepatic insufficiency).\n* Vascular claudication after \\<50 metres walking distance.\n* Severe renal impairment defined as glomerular filtration rate (GFR) ≤ 30 ml/min, uncontrolled and reno-vascular end stage renal disease.\n* Patients with diabetic polyneuropathies.\n* Any type of chronic diarrhoea or frequent diarrhoea (defined as \\>5 loose stools per day).\n* Faecal impaction and overflow diarrhoea.\n* Male patients with clinically diagnosed prostatic hyperplasia.\n* Clinically significant electrolyte abnormalities, e.g. clinically significant low/high potassium and low sodium.\n* Presence of clinical symptomatic haemorrhoids (grade III and IV), anal fissures or anorectal fistulas.\n* Less than 2 episodes of faecal incontinence (solids, liquid, gas or mucus) per week during the 4 week historical period prior to Visit 1 - Screening Visit.\n* Participation in a clinical drug study during the 90 days preceding the initial dose in this study.\n* Known history of allergy to methoxamine or any other ingredients of the Investigational Medicinal Product.\n* Patients who, in the opinion of the Investigator, are unsuitable for participation in the study due to any dependencies, general medical conditions or significant illness within two weeks prior to randomisation.\n* Use of any disallowed concomitant medication or other medication that the Investigator believes may affect the study including over-the-counter (OTC) products within 30 days prior to the Investigational Medicinal Product administration.\n* A personal or family history of QTcf prolongation or sudden death.\n* Patients taking Loperamide (2mg) \\>8 tablets per day for faecal incontinence either alone or in combination with codeine phosphate and/or paracetamol (8/500mg).\n* Patients using any device for the treatment of faecal incontinence."}, 'identificationModule': {'nctId': 'NCT01656720', 'briefTitle': 'A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period', 'organization': {'class': 'INDUSTRY', 'fullName': 'Norgine'}, 'officialTitle': 'A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period', 'orgStudyIdInfo': {'id': 'NRL001-01/2011 (SEFI)'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Placebo 2g Suppository', 'interventionNames': ['Drug: Placebo']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'NRL001 5mg', 'description': '5mg NRL001 in a 2g suppository', 'interventionNames': ['Drug: 1R, 2S-methoxamine hydrochloride']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'NRL001 7.5mg', 'description': '7.5mg NRL001 in a 2g suppository', 'interventionNames': ['Drug: 1R, 2S-methoxamine hydrochloride']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'NRL001 10mg', 'description': '10mg NRL001 in a 2g suppository', 'interventionNames': ['Drug: 1R, 2S-methoxamine hydrochloride']}], 'interventions': [{'name': '1R, 2S-methoxamine hydrochloride', 'type': 'DRUG', 'otherNames': ['NRL001'], 'armGroupLabels': ['NRL001 10mg', 'NRL001 5mg', 'NRL001 7.5mg']}, {'name': 'Placebo', 'type': 'DRUG', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '620 00', 'city': 'Brno', 'country': 'Czechia', 'facility': 'Fakultni Nemocnice BRNO', 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}, {'zip': '500 02', 'city': 'Hradec Králové', 'country': 'Czechia', 'facility': 'Gastroenterologie S R O', 'geoPoint': {'lat': 50.20923, 'lon': 15.83277}}, {'zip': '130 00', 'city': 'Liberec', 'country': 'Czechia', 'facility': 'Krajska Nemocnice Liberec', 'geoPoint': {'lat': 50.76711, 'lon': 15.05619}}, {'zip': '100 34', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Fakulni Nemocnice Kralovske', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '130 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Egk S.R.O Sanatoriu< Sv', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '130 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'GEP Clinic S.R.O', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '150 06', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Fakultni Nemocnice V Motole', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '180 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Fakultni Nemocnice Na Bulovce, Gynekologicko-Porodnicka Klinika', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '33000', 'city': 'Bordeaux', 'country': 'France', 'facility': 'Chu Bordeaux - Hopital St Andre', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'zip': '69003', 'city': 'Lyon', 'country': 'France', 'facility': 'Chu Lyon Groupement Hospitalier Edouard Herriot', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '44093', 'city': 'Nantes', 'country': 'France', 'facility': "Chu Nantes - Hotel Dieu - Institut Des Maladies De L'Appareil Digestif (IMAD)", 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'city': 'Rennes', 'country': 'France', 'facility': 'Dr Laurent Siproudhis', 'geoPoint': {'lat': 48.11109, 'lon': -1.67431}}, {'zip': '76031', 'city': 'Rouen', 'country': 'France', 'facility': 'Chu Rouen - Hopital De Charles Nicolle', 'geoPoint': {'lat': 49.44313, 'lon': 1.09932}}, {'zip': '14163', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Zentrum Fur Darm-Und Beckenchirurgie', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '14193', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Martin-Luther-Krankenhaus', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '69115', 'city': 'Heidelberg', 'country': 'Germany', 'facility': 'Universitats-Frauenklink', 'geoPoint': {'lat': 49.40768, 'lon': 8.69079}}, {'zip': 'H-1136', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'PMC Pannon Medical Center', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': 'H-1183', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Polyclinic for Outpatients, Szakrendelo Intezet', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '4032', 'city': 'Debrecen', 'country': 'Hungary', 'facility': 'University of Debrecen, Medical and Health Science Center', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': '6720', 'city': 'Szeged', 'country': 'Hungary', 'facility': 'University of Szeged, Albert Szent-Gyorgyi Clinical Center, Faculty of Medicine', 'geoPoint': {'lat': 46.253, 'lon': 20.14824}}, {'zip': 'H-2600', 'city': 'Vac Argenti', 'country': 'Hungary', 'facility': 'Javorszky Odon Hopsital'}, {'zip': 'H-8200', 'city': 'Veszprém', 'country': 'Hungary', 'facility': 'Csolnoky Ferenc Veszprem', 'geoPoint': {'lat': 47.09327, 'lon': 17.91149}}, {'zip': '20132', 'city': 'Milan', 'country': 'Italy', 'facility': 'Chirurgia Gastroenterologica', 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}, {'zip': '20159', 'city': 'Milan', 'country': 'Italy', 'facility': 'Casa Di Cura San Pio X', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '33170', 'city': 'Pordenone', 'country': 'Italy', 'facility': 'Seconda Unita Operativa Di Chirurgia Generale', 'geoPoint': {'lat': 45.95689, 'lon': 12.66051}}, {'zip': '00161', 'city': 'Rome', 'country': 'Italy', 'facility': 'Dipartimento Emergenza Urgenza', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '00161', 'city': 'Rome', 'country': 'Italy', 'facility': 'Unita Operativa Complessa Gastroenteroloogia A', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'city': 'Rome', 'country': 'Italy', 'facility': 'Unita Operativa Complessa Patologia Chirurgica A Indirizzo Gastroenterologico', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '85-079', 'city': 'Bydgoszcz', 'country': 'Poland', 'facility': 'Nzoz Vitamed', 'geoPoint': {'lat': 53.1235, 'lon': 18.00762}}, {'zip': '32-420', 'city': 'Gdów', 'country': 'Poland', 'facility': 'General And Proctology Surgeon', 'geoPoint': {'lat': 49.90818, 'lon': 20.19879}}, {'zip': '95-015', 'city': 'Głowno', 'country': 'Poland', 'facility': 'Centrum Medyczne, Wyzszej Szkoly Informatycznej', 'geoPoint': {'lat': 51.96463, 'lon': 19.71565}}, {'zip': '40-079', 'city': 'Katowice', 'country': 'Poland', 'facility': 'Nzoz Mekmed S.C. Przychondnia Lekarska', 'geoPoint': {'lat': 50.2597, 'lon': 19.02173}}, {'zip': '94-238', 'city': 'Lodz', 'country': 'Poland', 'facility': 'Nzoz Mikomed', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '14-100', 'city': 'Ostróda', 'country': 'Poland', 'facility': 'Osrodek Badawczo - Leczniczy Zbigniew Zegota', 'geoPoint': {'lat': 53.69671, 'lon': 19.96486}}, {'zip': '81-756', 'city': 'Sopot', 'country': 'Poland', 'facility': 'Endoskopia', 'geoPoint': {'lat': 54.4418, 'lon': 18.56003}}, {'zip': '21-040', 'city': 'Świdnik', 'country': 'Poland', 'facility': 'Lubelskie Centrum Diagnostyczne', 'geoPoint': {'lat': 51.21898, 'lon': 22.69621}}, {'zip': '01-231', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Lecznica Prosen SMO Private Medical Health Care Centre', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '53-333', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'Ars Medica SC', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '08035', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital Valle De Hebron', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08036', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital Clinic De Barcelona', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08304', 'city': 'Mataró', 'country': 'Spain', 'facility': 'Hospital De Mataro', 'geoPoint': {'lat': 41.54211, 'lon': 2.4445}}, {'zip': '29603', 'city': 'Málaga', 'country': 'Spain', 'facility': 'USP, Hospital De Marbella', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'zip': '50009', 'city': 'Zaragoza', 'country': 'Spain', 'facility': 'Hospital Clinico Universtiaria Lozana Blesa', 'geoPoint': {'lat': 41.65606, 'lon': -0.87734}}, {'zip': '205 02', 'city': 'Malmo', 'country': 'Sweden', 'facility': 'Pelvic Floor Centre', 'geoPoint': {'lat': 55.60587, 'lon': 13.00073}}, {'zip': '70362', 'city': 'Örebro', 'country': 'Sweden', 'facility': 'Kirurgiska Kliniken Universitetssjukhuset', 'geoPoint': {'lat': 59.27412, 'lon': 15.2066}}, {'zip': '141 86', 'city': 'Stockholm', 'country': 'Sweden', 'facility': 'Enheten For Nedre Abdominell Kirurgi', 'geoPoint': {'lat': 59.32938, 'lon': 18.06871}}, {'zip': '75185', 'city': 'Uppsala', 'country': 'Sweden', 'facility': 'Institute of Surgical Sciences', 'geoPoint': {'lat': 59.85882, 'lon': 17.63889}}, {'zip': 'HA1 3UJ', 'city': 'London', 'country': 'United Kingdom', 'facility': "St Mark's Hospital", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'NW1 2BU', 'city': 'London', 'country': 'United Kingdom', 'facility': 'University College Hospital', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'NG7 2UH', 'city': 'Nottingham', 'country': 'United Kingdom', 'facility': 'Queens Medical Centre', 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}, {'zip': 'S5 7AU', 'city': 'Sheffield', 'country': 'United Kingdom', 'facility': 'Nothern General Hopsital', 'geoPoint': {'lat': 53.38297, 'lon': -1.4659}}], 'overallOfficials': [{'name': 'Laurent Siproudhis, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hopital Pontchaillou'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Norgine', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}